Related Experiment Videos
Heparins attenuate cancer metastasis: are selectins the link?
1Zurich Center for Integrative Human Physiology, Institute of Physiology, University of Zurich, Zurich, Switzerland.
Abstract:
Heparin is often used to prevent or treat thromboembolism in cancer patients. Clinical and experimental evidence suggest that heparin also has anticancer activities. Experimental evidence consistently supports the ability of heparin to attenuate metastasis. The potential antimetastatic effects of heparin include inhibition of cell-cell interactions and heparanase and modulation of growth factors, and anticoagulant activity. Heparin inhibits selectin-mediated interactions of tumor cells with leukocytes, platelets, and endothelial cells, which are likely to mediate the initial steps of hematogenous metastasis. Prospective clinical trials can be designed on the basis of the insights obtained from experimental studies.
Related Concept Videos
Selectins
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
Intracellular Signaling Affects Focal Adhesions
Some...
Mitogens and the Cell Cycle